ArticleNeurology(R) neuroimmunology & neuroinflammation2026
Ganglion Cell Layer Compared With Inner Plexiform Layer Atrophy After Optic Neuritis Associated With NMOSD, MOGAD, and MS.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesOptic neuritis (ON) is a common manifestation of multiple sclerosis (MS), aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Compared with MS-ON, AQP4-ON and MOGAD-ON eyes exhibit more severe thinning of the macular composite ganglion cell + inner plexiform layer (GCIPL), as measured by optical coherence tomography (OCT). The individual measurement of the ganglion cell (GCL) and inner plexiform (IPL) layers, typically assessed together as the composite GCIPL thickness, has remained largely unexplored. In this study, we aimed to examine the relative contribution of GCL and IPL thinning to overall GCIPL thinning in MS-ON, AQP4-ON, and MOGAD-ON eyes.
methodsFor the cross-sectional analysis, MS, AQP4+NMOSD, and MOGAD participants with a history of ON >6 months prior and healthy controls (HC) underwent retinal imaging. For the longitudinal analysis, the evolution of GCL and IPL thinning was examined in people with baseline OCT within 30 days of a first episode of acute ON.
resultsIn the cross-sectional cohort, GCL and IPL volumes were lower in AQP4-ON (n = 30 eyes) and MOGAD-ON (n = 47 eyes), as compared with MS-ON (n = 66 eyes), but did not differ between AQP4-ON and MOGAD-ON eyes. The GCL/GCIPL ratio was lower in ON eyes relative to HC and was correlated with GCIPL volume, with a similar pattern across disease groups. AQP4-ON and MOGAD-ON eyes had a lower GCL/GCIPL ratio compared with MS-ON, with no significant difference between AQP4-ON and MOGAD-ON. In the longitudinal cohort, the GCL/GCIPL ratio was already reduced in the ON eyes (n = 19 eyes) compared with the fellow non-ON eyes at the baseline scan within the first month from ON (-1.01% [-1.59% to -0.44%], DISCUSSION: More severe GCIPL thinning after ON was associated with a lower GCL/GCIPL ratio, supporting that more GCL than IPL thinning occurs after ON. The pattern was similar across neuroinflammatory conditions including MS, MOGAD, and AQP4+NMOSD. Our findings may help shed light into dynamics of inner retinal layer atrophy after ON.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.